Alex Rovira

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3416646/publications.pdf

Version: 2024-02-01

194 papers	14,889 citations	29994 54 h-index	20900 115 g-index
199 all docs	199 docs citations	199 times ranked	14091 citing authors

#	Article	IF	Citations
1	Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke. New England Journal of Medicine, 2015, 372, 2296-2306.	13.9	4,059
2	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurology, The, 2016, 15, 292-303.	4.9	679
3	Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurology, The, 2015, 14, 302-317.	4.9	437
4	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosisâ€"establishing disease prognosis and monitoring patients. Nature Reviews Neurology, 2015, 11, 597-606.	4.9	422
5	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain, 2015, 138, 1863-1874.	3.7	403
6	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosisâ€"clinical implementation in the diagnostic process. Nature Reviews Neurology, 2015, 11, 471-482.	4.9	354
7	2021 MAGNIMSâ€"CMSCâ€"NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurology, The, 2021, 20, 653-670.	4.9	302
8	Deep gray matter volume loss drives disability worsening in multiple sclerosis. Annals of Neurology, 2018, 83, 210-222.	2.8	295
9	Improving automated multiple sclerosis lesion segmentation with a cascaded 3D convolutional neural network approach. NeuroImage, 2017, 155, 159-168.	2.1	287
10	Progression of regional grey matter atrophy in multiple sclerosis. Brain, 2018, 141, 1665-1677.	3.7	269
11	Brain atrophy and lesion load predict long term disability in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1082-1091.	0.9	267
12	BleedingRiskAnalysis inStrokeImaging Before ThromboLysis (BRASIL). Stroke, 2007, 38, 2738-2744.	1.0	240
13	The development of low-grade cerebral edema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation. Journal of Hepatology, 2001, 35, 598-604.	1.8	233
14	Association between pathological and MRI findings in multiple sclerosis. Lancet Neurology, The, 2019, 18, 198-210.	4.9	163
15	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nature Reviews Neurology, 2018, 14, 199-213.	4.9	157
16	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nature Reviews Neurology, 2020, 16, 171-182.	4.9	150
17	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	3.7	147
18	Posterior Fossa Reconstruction. Neurosurgery, 1994, 35, 874-885.	0.6	140

#	Article	IF	Citations
19	Hyperacute Ischemic Stroke: Middle Cerebral Artery Susceptibility Sign at Echo-planar Gradient-Echo MR Imaging. Radiology, 2004, 232, 466-473.	3.6	138
20	Hepatic encephalopathy is associated with posttransplant cognitive function and brain volume. Liver Transplantation, 2011, 17, 38-46.	1.3	129
21	Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. JAMA Neurology, 2019, 76, 1446.	4.5	119
22	A Single, Early Magnetic Resonance Imaging Study in the Diagnosis of Multiple Sclerosis. Archives of Neurology, 2009, 66, 587-92.	4.9	114
23	Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology, 2006, 43, 707-714.	3.6	113
24	Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. Journal of Neurology, 2016, 263, 1349-1360.	1.8	112
25	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	4.9	110
26	Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. Nature Reviews Neurology, 2015, 11, 676-686.	4.9	109
27	Predicting progression in primary progressive multiple sclerosis: A 10â€year multicenter study. Annals of Neurology, 2008, 63, 790-793.	2.8	101
28	Diffusion-weighted MR imaging in the acute phase of transient ischemic attacks. American Journal of Neuroradiology, 2002, 23, 77-83.	1.2	100
29	Magnetic resonance monitoring of lesion evolution in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2013, 6, 298-310.	1.5	98
30	Assessing response to interferon-Î² in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.5	98
31	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain, 2018, 141, 1075-1084.	3.7	98
32	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurology, The, 2018, 17, 133-142.	4.9	98
33	Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Multiple Sclerosis Journal, 2013, 19, 1175-1181.	1.4	93
34	MR in the diagnosis and monitoring of multiple sclerosis: An overview. European Journal of Radiology, 2008, 67, 409-414.	1.2	91
35	One-shot domain adaptation in multiple sclerosis lesion segmentation using convolutional neural networks. NeuroImage: Clinical, 2019, 21, 101638.	1.4	91
36	Unraveling treatment response in multiple sclerosis. Neurology, 2019, 92, 180-192.	1.5	88

#	Article	IF	Citations
37	Neurofilament light chain level is a weak risk factor for the development of MS. Neurology, 2016, 87, 1076-1084.	1.5	85
38	Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis. Brain, 2021, 144, 1296-1311.	3.7	81
39	Will Rogers phenomenon in multiple sclerosis. Annals of Neurology, 2008, 64, 428-433.	2.8	80
40	Hippocampal and Deep Gray Matter Nuclei Atrophy Is Relevant for Explaining Cognitive Impairment in MS: A Multicenter Study. American Journal of Neuroradiology, 2017, 38, 18-24.	1.2	80
41	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Multiple Sclerosis Journal, 2018, 24, 301-312.	1.4	79
42	Longitudinal Assessment of Multiple Sclerosis with the Brainâ€Age Paradigm. Annals of Neurology, 2020, 88, 93-105.	2.8	79
43	Decreased white matter lesion volume and improved cognitive function after liver transplantation. Hepatology, 2007, 46, 1485-1490.	3.6	78
44	Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. Multiple Sclerosis Journal, 2018, 24, 214-221.	1.4	77
45	Automated detection of multiple sclerosis lesions in serial brain MRI. Neuroradiology, 2012, 54, 787-807.	1.1	76
46	A toolbox for multiple sclerosis lesion segmentation. Neuroradiology, 2015, 57, 1031-1043.	1.1	76
47	Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 1001-1008.	1.2	68
48	Identifying Progression in Multiple Sclerosis: New Perspectives. Annals of Neurology, 2020, 88, 438-452.	2.8	67
49	Generic acquisition protocol for quantitative MRI of the spinal cord. Nature Protocols, 2021, 16, 4611-4632.	5.5	65
50	Brain Atrophy in Multiple Sclerosis. Neuroimaging Clinics of North America, 2017, 27, 289-300.	0.5	64
51	T2 hyperintensity along the cortico-spinal tract in cirrhosis relates to functional abnormalities. Hepatology, 2003, 38, 1026-1033.	3.6	60
52	Disability progression markers over 6â€“12â€‰years in interferon-Î²-treated multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 322-330.	1.4	60
53	MRI findings in aphasic status epilepticus. Epilepsia, 2008, 49, 1465-1469.	2.6	59
54	Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report. American Journal of Neuroradiology, 2002, 23, 989-94.	1.2	56

#	Article	IF	Citations
55	Automated tissue segmentation of MR brain images in the presence of white matter lesions. Medical Image Analysis, 2017, 35, 446-457.	7.0	55
56	Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS). Frontiers in Neurology, 2020, 11, 632.	1.1	52
57	CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1027-1038.	0.9	51
58	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology, 2019, 92, e1507-e1516.	1.5	49
59	Brain Magnetic Resonance in Hepatic Encephalopathy. Seminars in Ultrasound, CT and MRI, 2014, 35, 136-152.	0.7	48
60	A subtraction pipeline for automatic detection of new appearing multiple sclerosis lesions in longitudinal studies. Neuroradiology, 2014, 56, 363-374.	1.1	47
61	Determinants of iron accumulation in deep grey matter of multiple sclerosis patients. Multiple Sclerosis Journal, 2014, 20, 1692-1698.	1.4	47
62	Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging. Radiology, 2018, 288, 554-564.	3.6	47
63	Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. NeuroImage: Clinical, 2018, 19, 466-475.	1.4	47
64	Multiple Sclerosis Lesion Synthesis in MRI Using an Encoder-Decoder U-NET. IEEE Access, 2019, 7, 25171-25184.	2.6	46
65	Mind the gap: from neurons to networks to outcomes in multiple sclerosis. Nature Reviews Neurology, 2021, 17, 173-184.	4.9	46
66	Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis. Archives of Neurology, 2011, 68, 1421.	4.9	44
67	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. Neurology, 2016, 87, 1368-1374.	1.5	42
68	Brain Magnetic Resonance Spectroscopy in Episodic Hepatic Encephalopathy. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 272-277.	2.4	41
69	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. Multiple Sclerosis Journal, 2020, 26, 1658-1669.	1.4	41
70	Neurological damage after transcatheter aortic valve implantation compared with surgical aortic valve replacement in intermediate risk patients. Clinical Research in Cardiology, 2016, 105, 508-517.	1.5	40
71	A fully convolutional neural network for new T2-w lesion detection in multiple sclerosis. NeuroImage: Clinical, 2020, 25, 102149.	1.4	40
72	Automatic multiple sclerosis lesion detection in brain MRI by FLAIR thresholding. Computer Methods and Programs in Biomedicine, 2014, 115, 147-161.	2.6	39

#	Article	IF	Citations
73	A supervised framework with intensity subtraction and deformation field features for the detection of new T2-w lesions in multiple sclerosis. NeuroImage: Clinical, 2018, 17, 607-615.	1.4	39
74	Exposure to gadolinium and neurotoxicity: current status of preclinical and clinical studies. Neuroradiology, 2020, 62, 925-934.	1.1	39
75	Oral glutamine challenge and magnetic resonance spectroscopy in three patients with congenital portosystemic shunts. Journal of Hepatology, 2004, 40, 552-557.	1.8	37
76	Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. Neurology, 2019, 93, e1852-e1866.	1.5	37
77	Evaluating the response to glatiramer acetate in relapsingâ€“remitting multiple sclerosis (RRMS) patients. Multiple Sclerosis Journal, 2014, 20, 1602-1608.	1.4	36
78	Power estimation for non-standardized multisite studies. NeuroImage, 2016, 134, 281-294.	2.1	36
79	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. Neurology, 2021, 97, e1641-e1652.	1.5	35
80	Treating relapsingâ€“remitting multiple sclerosis: therapy effects on brain atrophy. Journal of Neurology, 2015, 262, 2617-2626.	1.8	34
81	Specificity of Barkhof Criteria in Predicting Conversion to Multiple Sclerosis When Applied to Clinically Isolated Brainstem Syndromes. Archives of Neurology, 2004, 61, 222.	4.9	32
82	MARGA: Multispectral Adaptive Region Growing Algorithm for brain extraction on axial MRI. Computer Methods and Programs in Biomedicine, 2014, 113, 655-673.	2.6	32
83	Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral. Annals of Neurology, 2019, 86, 704-713.	2.8	32
84	Optic Nerve Topography in Multiple Sclerosis Diagnosis. Neurology, 2021, 96, e482-e490.	1.5	32
85	1H Magnetic Resonance Spectroscopy in Multiple Sclerosis and Related Disorders. Neuroimaging Clinics of North America, 2013, 23, 459-474.	0.5	31
86	Early predictors of multiple sclerosis after a typical clinically isolated syndrome. Multiple Sclerosis Journal, 2014, 20, 1721-1726.	1.4	31
87	Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex. Journal of Neuro-Oncology, 2014, 118, 205-223.	1.4	31
88	Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling. NeuroImage: Clinical, 2015, 9, 640-647.	1.4	31
89	Maximal Admission Core Lesion Compatible With Favorable Outcome in Acute Stroke Patients Undergoing Endovascular Procedures. Stroke, 2015, 46, 2849-2852.	1.0	31
90	MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. Human Molecular Genetics, 2016, 25, 308-316.	1.4	31

#	Article	IF	Citations
91	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. Neurology, 2022, 98, .	1.5	31
92	Improved Automatic Detection of New T2 Lesions in Multiple Sclerosis Using Deformation Fields. American Journal of Neuroradiology, 2016, 37, 1816-1823.	1.2	30
93	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective. JAMA Neurology, 2021, 78, 351.	4.5	30
94	MR imaging in hyperacute ischemic stroke. European Journal of Radiology, 2017, 96, 125-132.	1.2	29
95	BOOST: A supervised approach for multiple sclerosis lesion segmentation. Journal of Neuroscience Methods, 2014, 237, 108-117.	1.3	28
96	Predictive value of early brain atrophy on response in patients treated with interferon Î². Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e132.	3.1	28
97	Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis. Neurology, 2021, 96, e1561-e1573.	1.5	28
98	Lesion topographies in multiple sclerosis diagnosis. Neurology, 2017, 89, 2351-2356.	1.5	27
99	Ratio of T1-Weighted to T2-Weighted Signal Intensity as a Measure of Tissue Integrity: Comparison with Magnetization Transfer Ratio in Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 461-463.	1.2	27
100	Open-access quantitative MRI data of the spinal cord and reproducibility across participants, sites and manufacturers. Scientific Data, 2021, 8, 219.	2.4	27
101	Magnetic resonance imaging measurement of brain edema in patients with liver disease: resolution after transplantation. Current Opinion in Neurology, 2002, 15, 731-737.	1.8	26
102	Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement. European Radiology, 2019, 29, 3959-3967.	2.3	26
103	Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. Multiple Sclerosis Journal, 2014, 20, 1471-1477.	1.4	25
104	Peri-ictal magnetic resonance imaging in status epilepticus: Temporal relationship and prognostic value in 60 patients. Seizure: the Journal of the British Epilepsy Association, 2019, 71, 289-294.	0.9	25
105	Gadolinium Deposition Safety: Seeking the Patientâ€™s Perspective. American Journal of Neuroradiology, 2020, 41, 944-946.	1.2	25
106	Robust association between vascular habitats and patient prognosis in glioblastoma: An international multicenter study. Journal of Magnetic Resonance Imaging, 2020, 51, 1478-1486.	1.9	24
107	A critical appraisal of the quality of low back pain practice guidelines using the AGREE II tool and comparison with previous evaluations: a EuroAIM initiative. European Spine Journal, 2018, 27, 2781-2790.	1.0	22
108	Usefulness of brain perfusion CT in focalâ€onset status epilepticus. Epilepsia, 2019, 60, 1317-1324.	2.6	22

#	Article	IF	Citations
109	Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study. Multiple Sclerosis Journal, 2019, 25, 352-360.	1.4	22
110	Brain Volume Loss During the First Year of Interferonâ€Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. Journal of Neuroimaging, 2016, 26, 532-538.	1.0	21
111	Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Multiple Sclerosis Journal, 2017, 23, 556-566.	1.4	21
112	Procedural approaches and angiographic signs predicting first-pass recanalization in patients treated with mechanical thrombectomy for acute ischaemic stroke. Interventional Neuroradiology, 2019, 25, 491-496.	0.7	21
113	The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?. Multiple Sclerosis Journal, 2016, 22, 18-33.	1.4	20
114	MR Imaging in Monitoring and Predicting Treatment Response in Multiple Sclerosis. Neuroimaging Clinics of North America, 2017, 27, 277-287.	0.5	20
115	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. Multiple Sclerosis Journal, 2021, 27, 913-921.	1.4	20
116	Evaluating the effect of multiple sclerosis lesions on automatic brain structure segmentation. NeuroImage: Clinical, 2017, 15, 228-238.	1.4	19
117	Chelated or dechelated gadolinium deposition. Lancet Neurology, The, 2017, 16, 955.	4.9	19
118	An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy. Multiple Sclerosis Journal, 2016, 22, 842-846.	1.4	18
119	Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 316-318.	0.9	18
120	Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 399-404.	1.2	17
121	Texture analysis in susceptibility-weighted imaging may be useful to differentiate acute from chronic multiple sclerosis lesions. European Radiology, 2020, 30, 6348-6356.	2.3	16
122	MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas. European Radiology, 2021, 31, 1738-1747.	2.3	16
123	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. European Journal of Neurology, 2022, 29, 1075-1081.	1.7	16
124	Scoring the 10â€year risk of ambulatory disability in multiple sclerosis: the RoAD score. European Journal of Neurology, 2021, 28, 2533-2542.	1.7	16
125	Improvement of magnetic resonance spectroscopic abnormalities but not pallidal hyperintensity followed amelioration of hepatic encephalopathy after occlusion of a large splenoâ€“renal shunt. Journal of Hepatology, 2001, 34, 177-178.	1.8	15
126	Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome. Neuroradiology, 2019, 61, 667-674.	1.1	15

#	Article	IF	Citations
127	Juxtacortical Lesions and Cortical Thinning in Multiple Sclerosis. American Journal of Neuroradiology, 2015, 36, 2270-2276.	1.2	14
128	A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis. BMC Neurology, 2016, 16, 240.	0.8	14
129	Classic Block Design â€œPseudoâ€â€Restingâ€State fMRI Changes After a Neurorehabilitation Program in Patients with Multiple Sclerosis. Journal of Neuroimaging, 2018, 28, 313-319.	1.0	14
130	Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort. Journal of Neurology, 2020, 267, 3541-3554.	1.8	14
131	Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 388-391.	0.9	14
132	Cerebrovascular disease burden in late-onset non-lesional focal epilepsy. Seizure: the Journal of the British Epilepsy Association, 2019, 66, 31-35.	0.9	13
133	T1/T2-weighted ratio in multiple sclerosis: A longitudinal study with clinical associations. NeuroImage: Clinical, 2022, 34, 102967.	1.4	13
134	Cephalometric oropharynx and oral cavity analysis in Chiari malformation Type I: a retrospective case-control study. Journal of Neurosurgery, 2017, 126, 626-633.	0.9	12
135	Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2017, 38, 1486-1493.	1.2	12
136	The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria. Brain, 2022, 145, 3931-3942.	3.7	12
137	Serial proton spectroscopy, magnetization transfer ratio andT2relaxation in pseudotumoral demyelinating lesions. NMR in Biomedicine, 2002, 15, 284-292.	1.6	11
138	MAGNIMS recommendations for harmonization of MRI data in MS multicenter studies. NeuroImage: Clinical, 2022, 34, 102972.	1.4	11
139	Usefulness of magnetic resonance spectroscopy for diagnosis of hepatic encephalopathy in a patient with relapsing confusional syndrome. Digestive Diseases and Sciences, 2001, 46, 2451-2455.	1.1	10
140	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. Multiple Sclerosis Journal, 2015, 21, 1802-1810.	1.4	10
141	ESNR Presidential Address, 2017. Neuroradiology, 2017, 59, 1-2.	1.1	10
142	Tumefactive inflammatory leukoencephalopathy in cocaine users: Report of three cases. Multiple Sclerosis and Related Disorders, 2020, 38, 101496.	0.9	10
143	A validation study of manual atrophy measures in patients with MultipleÂSclerosis. Neuroradiology, 2020, 62, 955-964.	1.1	10
144	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. Multiple Sclerosis Journal, 2022, 28, 71-81.	1.4	10

#	Article	IF	Citations
145	Cortical metabolic and structural differences in patients with chronic migraine. An exploratory 18FDG-PET and MRI study. Journal of Headache and Pain, 2021, 22, 75.	2.5	10
146	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsingâ€“remitting multiple sclerosis patients. Journal of Neurology, 2022, 269, 452-459.	1.8	10
147	Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings. Multiple Sclerosis and Related Disorders, 2021, 55, 103146.	0.9	10
148	Spinal Cord in Multiple Sclerosis: Magnetic Resonance Imaging Features and Differential Diagnosis. Seminars in Ultrasound, CT and MRI, 2016, 37, 396-410.	0.7	9
149	Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images. American Journal of Neuroradiology, 2017, 38, 250-256.	1.2	9
150	Gadolinium should always be used to assess disease activity in MS â€“ No. Multiple Sclerosis Journal, 2020, 26, 767-769.	1.4	9
151	Idiopathic Inflammatory Demyelinating Diseases of the Brainstem. Seminars in Ultrasound, CT and MRI, 2013, 34, 123-130.	0.7	8
152	Effects of diazoxide in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e147.	3.1	8
153	Other noninfectious inflammatory disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 425-446.	1.0	8
154	Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. Frontiers in Neurology, 2021, 12, 693333.	1.1	8
155	Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 732-740.	0.9	8
156	Circulating Aquaporin-4 as A biomarker of early neurological improvement in stroke patients: A pilot study. Neuroscience Letters, 2020, 714, 134580.	1.0	7
157	Assessing the Accuracy and Reproducibility of <scp>PARIETAL</scp>: A Deep Learning Brain Extraction Algorithm. Journal of Magnetic Resonance Imaging, 2021, , .	1.9	7
158	Beyond McDonald: updated perspectives on MRI diagnosis of multiple sclerosis. Expert Review of Neurotherapeutics, 2021, 21, 895-911.	1.4	7
159	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 950-957.	1.4	7
160	Spinal cord MRI should always be performed in clinically isolated syndrome patients: No. Multiple Sclerosis Journal, 2014, 20, 1686-1687.	1.4	6
161	Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. Multiple Sclerosis Journal, 2018, 24, 721-727.	1.4	6
162	Predictors of response to endovascular treatment of posterior circulation stroke. European Journal of Radiology, 2019, 116, 219-224.	1.2	6

#	Article	IF	Citations
163	REMOTE Ischemic Perconditioning Among Acute Ischemic Stroke Patients in Catalonia: REMOTE-CAT PROJECT. Frontiers in Neurology, 2020, 11, 569696.	1.1	6
164	MRI monitoring of spinal cord changes in patients with multiple sclerosis. Current Opinion in Neurology, 2016, 29, 445-452.	1.8	5
165	Differential effect of vascularity between longâ€•and shortâ€term survivors with IDH1/2 wildâ€type glioblastoma. NMR in Biomedicine, 2021, 34, e4462.	1.6	5
166	Early experience with a novel net temporary bridging device (Cascade) to assist endovascular coil embolization of intracranial aneurysms. Journal of Neurosurgery, 2021, 134, 591-599.	0.9	5
167	Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage. Journal of Clinical Medicine, 2021, 10, 989.	1.0	5
168	Transductive Transfer Learning for Domain Adaptation in Brain Magnetic Resonance Image Segmentation. Frontiers in Neuroscience, 2021, 15, 608808.	1.4	5
169	Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies. Neurodegenerative Disease Management, 2021, 11, 251-261.	1.2	5
170	Magnetic resonance imaging findings in focalâ€•onset status epilepticus. European Journal of Neurology, 2022, 29, 3-11.	1.7	5
171	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. Journal of Neurology, 2022, 269, 1764-1772.	1.8	5
172	Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients. Multiple Sclerosis Journal, 2022, 28, 1209-1218.	1.4	4
173	T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis â€“ Commentary. Multiple Sclerosis Journal, 2022, 28, 357-358.	1.4	4
174	Use of gadolinium for MRI diagnostic or surveillance studies in patients with MS. Neurology, 2019, 93, 239-240.	1.5	3
175	Assessment of brain volumes obtained from MP-RAGE and MP2RAGE images, quantified using different segmentation methods. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2020, 33, 757-767.	1.1	3
176	The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease. Multiple Sclerosis Journal, 2021, 27, 968-972.	1.4	3
177	Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis. Multiple Sclerosis Journal, 2022, 28, 885-899.	1.4	3
178	NMO spectrum disorders: how wide is the spectrum?. Multiple Sclerosis Journal, 2014, 20, 1417-1419.	1.4	2
179	Trajectories of subcortical iron accumulation in MS. Neurology, 2015, 84, 2388-2389.	1.5	2
180	Secondary progressive NMO, or concomitant NMO and a primary neurodegenerative disorder?. Multiple Sclerosis Journal, 2015, 21, 1876-1878.	1.4	2

#	Article	IF	Citations
181	Imaging of meningeal inflammation should become part of the routine MRI protocol â€“ Commentary. Multiple Sclerosis Journal, 2019, 25, 333-335.	1.4	2
182	Adding brain volume measures into response criteria in multiple sclerosis: the RÃo-4 score. Neuroradiology, 2021, 63, 1031-1041.	1.1	2
183	MR imaging findings in primary spinal cord glioblastoma. Radiology Case Reports, 2021, 16, 72-77.	0.2	2
184	Quantitative comparison of subcortical and ventricular volumetry derived from MPRAGE and MP2RAGE images using different brain morphometry software. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2021, 34, 903-914.	1.1	2
185	Prognosis of a second clinical event from baseline MRI in patients with a CIS: a multicenter study using a machine learning approach. Neuroradiology, 2022, 64, 1383-1390.	1.1	2
186	SWI as an Alternative to Contrast-Enhanced Imaging to Detect Acute MS Lesions. American Journal of Neuroradiology, 2022, 43, 534-539.	1.2	2
187	Assessment of 2D conventional and synthetic MRI in multiple sclerosis. Neuroradiology, 2022, , .	1.1	2
188	Routine Gadolinium Use for MRI Follow-Up of Multiple Sclerosis: Counterpointâ€”Gadolinium Should Not Always Be Used to Assess Disease Activity. American Journal of Roentgenology, 2022, 219, 26-27.	1.0	1
189	Spinal cord grey matter atrophy in Multiple Sclerosis clinical practice. Neuroscience Informatics, 2022, 2, 100071.	2.8	1
190	Foreword 1. , 0, , xviii-xviii.		0
191	Advances in the Diagnosis, Characterization, and Monitoring of Multiple Sclerosis. Neuroimaging Clinics of North America, 2017, 27, xvii-xviii.	0.5	0
192	Testing the Food Experience in Healthy Human Volunteers: a Proof-of-Concept Study. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 65-68.	0.5	0
193	Can Cognitive training Reignite Compensatory Mechanisms in Advanced Multiple Sclerosis Patients? An Explorative Morphological Network Approach. Neuroscience, 2022, , .	1.1	0
194	The reality of multiple sclerosis assessment in middle-income countries â€“ Authors' reply. Lancet Neurology, The, 2022, 21, 215-216.	4.9	0